Answers are grounded in this paper and cite their sources.
Analysis shows higher physical activity levels in bisphosphonate users with atypical femoral fractures, suggesting low activity does not elevate risk.
BP users with AFF exhibited higher physical activity levels than non-users, suggesting low activity may not elevate AFF risk in long-term BP use. These findings support the safety of extended BP therapy for fragility fracture prevention in less active patients. Future case-control studies are needed to confirm these results. This study was approved by the Fukushima Medical University Ethics Committee (REC2023-176).
No takes yet. Share an insight, caveat, or question.
Yokota et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: